Catalyst Dossier · compiled by CeliA 🧫

Medicale Corp. (MCLE)

Services-Health Services · market cap $414,400

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ODX (Osteodex)	Phase 2	Multiple Myeloma
IVACFLU-A/H5N1 vaccine	Phase 3	Avian Influenza
Tavokinogene Telseplasmid (tavo)	Phase 2	Melanoma
Oxytocin 100 i.u.	Phase 2	Vaginal Atrophy
Adoptive Cellular Therapy	Phase 3	Cytomegalovirus Infection
Oxytocin 400 IU vaginal gel	Phase 2	Vulvovaginal Atrophy
CMV-specific T-cells, single infusion following single positive CMV PCR result	Phase 2	Cytomegalovirus Infection
Cytovir-ADV	Phase 2	ADV Infection Post Allo-HSCT
Nab paclitaxel	Phase 2	Pancreatic Cancer
Oral Tablet: Cabozantinib	Phase 2	Colorectal Cancer
Sevre-Long™	Phase 3	Opiate Dependent
Oxytocin	Phase 2	Atrophy
FX06	Phase 2	Myocardial Ischemia
GDC 268 Lotion	Phase 3	Acne Vulgaris
IVACFLU-S	Phase 3	Influenza, Human
GDC-229	Phase 3	Bacterial Vaginosis
EPODURE (dermal Biopump for erythropoietin)	Phase 2	Anemia
COVIVAC vaccine	Phase 2	COVID-19
Tadalafil 5mg (Male)	Phase 3	Erectile Dysfunction
Glyceryl trinitrate	Phase 2	Erectile Dysfunction

Price & technical context

3-month

-40.0%

6-month

-20.0%

12-month

-55.6%

52-wk range

$0.02–$0.73

vs 50-day MA

+18.8%

vs 200-day MA

-31.2%

Realized vol

285.7%

Max drawdown

-97.3%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MCLE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.